
Event Description
Because their disease cannot be tracked through normal blood labs, nonsecretory myeloma patients are always looking for new ways to monitor their disease. A new solution may be found in the upcoming test, mass spectrometry. This test could use nonsecretor blood labs to accurately monitor the disease.
Here to teach us more about the future of mass spectrometry for nonsecretory multiple myeloma is specialist Dr. Faith Davies from NYU Langone. Come with your questions!
Schedule & Agenda

Vicki introduces the agenda of the event.

Vicki introduces the agenda of the event.

Dr. Davies talks about the future of mass spectrometry for nonsecretory multiple myeloma.

Dr. Davies talks about the future of mass spectrometry for nonsecretory multiple myeloma.
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Vicki has been fighting Myeloma since 2004 when she was diagnosed with stage 2 Myeloma and began aggressive chemotherapy. After a stem cell transplant in 2007 from which she obtained a very good partial response, Vicki has been on just about every drug regimen available. Every drug has worked well but, of course, nothing works forever. Recently after being IGA lambda for over 17 years, Vicki became a non-secretor and now leads Healthtree’s non secretory community group. Throughout her myeloma journey, Vicki has gratefully maintained an excellent quality of life and now finds joy in helping others diagnosed with Myeloma.

Faith Davies, MBBCh, MRCP, MD, FRCPath, is a member of the faculty of the Department of Medicine at New York University Langone Health and Director of the Clinical Myeloma Program at the Perlmutter Cancer Center. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Her focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting. Prior to joining NYU Langone Health, Dr. Davies was Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS). She also served as Professor of Medicine and Director of the Phase I Clinical Trials Program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute. Dr. Davies came to UAMS in 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed her general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:







.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)